3.87

11.85% 0.41

After Hours: 3.85 -0.02 -0.52%

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Financials Discussions Forecast

Prime Medicine Inc stock is traded at $3.87, with a volume of 33.15M. It is up +11.85% in the last 24 hours and down -9.58% over the past month. Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Previous Close:

$3.46

Open:

$4.23

24h Volume:

33.15M

Relative Volume:

27.92

Market Cap:

$468.12M

Revenue:

Net Income/Loss:

$-217.44M

P/E Ratio:

-2.0935

EPS:

-1.8486

Net Cash Flow:

$-205.20M

1W Performance:

+7.50%

1M Performance:

-9.58%

6M Performance:

-44.71%

1Y Performance:

-59.43%

1-Day Range:

$3.815

$5.02

1-Week Range:

$3.39

$5.02

52-Week Range:

$3.39

$9.86

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617-465-0013

Address

60 FIRST ST., CAMBRIDGE

Employee

234

Twitter

Next Earnings Date

Latest SEC Filings

PRME's Discussions on Twitter

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

06:08 AM

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday - The Motley Fool

06:08 AM

03:41 AM

Prime Medicine shares rise on $3.5 billion BMS collaboration - Investing.com

03:41 AM

02:26 AM

Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline - BioSpace

02:26 AM

01:56 AM

Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb - MedCity News

01:56 AM

01:36 AM

Prime Medicine shares hold Buy rating amid BMS deal By Investing.com - Investing.com UK

12:14 PM

11:55 AM

Bristol, Prime Medicine in deal to develop T-cell therapies - Seeking Alpha

11:55 AM

11:34 AM

Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline - Genetic Engineering & Biotechnology News

11:34 AM

11:12 AM

Prime Medicine soars as it inks research collab with BMS - The Pharma Letter

11:12 AM

10:38 AM

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - AOL

10:38 AM

10:12 AM

Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley - TipRanks

10:12 AM

09:42 AM

Prime Medicine pact with Bristol doesn’t change thesis, says Stifel - TipRanks

09:42 AM

09:00 AM

A radiopharmaceuticals startup raises $175 million - STAT

09:00 AM

08:51 AM

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb - MarketWatch

08:51 AM

08:38 AM

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Benzinga

08:38 AM

08:28 AM

Prime Medicine focuses on key genetic therapy programs By Investing.com - Investing.com Canada

08:28 AM

08:00 AM

Prime Medicine Strikes $3.5B Deal for T-Cell Therapy Advances - TipRanks

08:00 AM

07:29 AM

Prime Medicine rises after investment from Bristol Myers, licensing deal - XM

07:29 AM

07:28 AM

Prime Medicine unveils strategically focused pipeline - TipRanks

07:28 AM

07:18 AM

Prime Medicine, Bristol Myers Squibb ink gene editing deal By Investing.com - Investing.com UK

07:18 AM

07:03 AM

Prime Medicine Unveils Strategically Focused Pipeline - GlobeNewswire

07:03 AM

07:02 AM

Prime Medicine Unveils Strategically Focused Pipeline - The Bakersfield Californian

07:02 AM

Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb - STAT

07:02 AM

07:01 AM

Prime Medicine Announces Strategic Research Collaboration - GlobeNewswire

07:01 AM

Prime Medicine Unveils Strategically Focused Pipeline - GlobeNewswire Inc.

07:01 AM

05:20 AM

Prime Medicine's SWOT analysis: gene editing firm's stock potential By Investing.com - Investing.com UK

05:20 AM

Sep 28, 2024

Benjamin F. Edwards & Company Inc. Purchases 24,899 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Sep 28, 2024

Sep 27, 2024

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Sep 27, 2024

Sep 25, 2024

Top investors say Prime Medicine Inc (PRME) ticks everything they need - SETE News

Sep 25, 2024

Sep 24, 2024

Citigroup Upgrades Prime Medicine (PRME) - MSN

Sep 24, 2024

Sep 23, 2024

Westwood Holdings Group Inc. Purchases 199,229 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat

Sep 23, 2024

Market Insight: Prime Medicine Inc (PRME)’s Notable Drop, Closing at 3.83 - The Dwinnex

Sep 23, 2024

Program supporting child mental health - CTV News Winnipeg

Sep 23, 2024

Prime Medicine Inc’s results are impressive - US Post News

Sep 23, 2024

Westwood Holdings Group Inc. Boosts Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Sep 23, 2024

Scilex (NASDAQ:SCLX) and Prime Medicine (NYSE:PRME) Critical Analysis - Defense World

Sep 23, 2024

Sep 22, 2024

Prime Medical Center Promotes Its Complete Personalised Care Experience on OOH - INSITE OOH

Sep 22, 2024

Bank of New York Mellon Corp Boosts Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Sep 22, 2024

Sep 21, 2024

FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq

Sep 21, 2024

Sep 19, 2024

There is no way Prime Medicine Inc (PRME) can keep these numbers up - SETE News

Sep 19, 2024

EmVenio Research celebrates Prime Healthcare partnership with ribbon-cutting - WV News

Sep 19, 2024

Sep 18, 2024